BioPharma Credit PLC
BOPCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.43 | -0.28 | 0.06 | -3.28 |
| FCF Yield | 10.36% | 11.20% | 14.12% | 7.25% |
| EV / EBITDA | 8.80 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 10.34% | 8.09% | 13.63% | 6.23% |
| Gross Margin | 100.00% | 69.19% | 86.19% | 69.60% |
| Cash Conversion Ratio | 0.92 | 1.14 | 1.01 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.50% | 8.10% | 30.60% | 0.61% |
| Free Cash Flow Growth | -9.15% | -33.15% | 91.09% | 66.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.05 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -305.36 | 0.00 |
| Cash Conversion Cycle | 79.75 | 46.23 | 32.68 | -116.75 |